/ricerca/ansaen/search.shtml?any=
Show less

Se hai scelto di non accettare i cookie di profilazione e tracciamento, puoi aderire all’abbonamento "Consentless" a un costo molto accessibile, oppure scegliere un altro abbonamento per accedere ad ANSA.it.

Ti invitiamo a leggere le Condizioni Generali di Servizio, la Cookie Policy e l'Informativa Privacy.

Puoi leggere tutti i titoli di ANSA.it
e 10 contenuti ogni 30 giorni
a €16,99/anno

  • Servizio equivalente a quello accessibile prestando il consenso ai cookie di profilazione pubblicitaria e tracciamento
  • Durata annuale (senza rinnovo automatico)
  • Un pop-up ti avvertirà che hai raggiunto i contenuti consentiti in 30 giorni (potrai continuare a vedere tutti i titoli del sito, ma per aprire altri contenuti dovrai attendere il successivo periodo di 30 giorni)
  • Pubblicità presente ma non profilata o gestibile mediante il pannello delle preferenze
  • Iscrizione alle Newsletter tematiche curate dalle redazioni ANSA.


Per accedere senza limiti a tutti i contenuti di ANSA.it

Scegli il piano di abbonamento più adatto alle tue esigenze.

EU still set to get 300 mn vaccine doses in Q2 - Schinas

EU still set to get 300 mn vaccine doses in Q2 - Schinas

EC VP says AstraZeneca case won't change distribution

ROME, 16 March 2021, 14:52

Redazione ANSA

ANSACheck

© ANSA/EPA

© ANSA/EPA
© ANSA/EPA

(see related stories on Astrazeneca, vaccines) European Commission Vice President Margaritis Schinas said Tuesday that the EU is still set to get 300 million doses of COVID-19 vaccines in the second quarter of this year, regardless of uncertainty about the AstraZeneca jab.
    "What is happening with AstraZeneca does not put into doubt the distribution of the doses, but their use," Schinas told ANSA in an interview.
    "We put this number of doses at the disposal of the member states, but we don't manage their vaccination plans.
    "It is reasonable to say that we remain on target because Pfizer is producing a lot more and because Johnson & Johnson has a new agreement with a site in Germany for 'fill and finish'".
    He said the EC will let the European Medicines Agency (EMA) decide on AstraZeneca, amid fears of links to blood clots.
    "Science guides the authorization of vaccines in the European system, not politics," Schinas said.
    "This wave of doubt puts the EMA at the centre but there is only one road for the European Commission, the road of the EMA.
    "We base our policy on science.
    "This is the European model.
    "The agency was created so that states would follow its recommendations not vice-versa "The EMA is sticking by its original assessment for now.
    "The agency is also talking to the British experts.
    "Thursday will be the day of truth".
    He said that the EC was not playing any geopolitical games with respect to the Russian Sputnik V vaccine.
    "Our enemy is the virus and we work for the European citizens, we don't work against anyone," Schinas said.
    "If Sputnik V is approved by the EMA and there is an appetite among the member States for the Commission to take action, we'll see".
   

ALL RIGHTS RESERVED © Copyright ANSA

Not to be missed

Share

Or use

ANSA Corporate

If it is news,
it is an ANSA.

We have been collecting, publishing and distributing journalistic information since 1945 with offices in Italy and around the world. Learn more about our services.